GI Flashcards
T staging for gastric cancer
T1a: lamina propria or muscularis mucosa, T1b: invades submucosa, T2: invades muscularis propria, T#: invades subserosa, T4a: invades serosa, T4b: invades adjacent structures
Management of cT1-2N0 anal
chemoradiation 42/5040
Liver mean constraint during gastric RT
mean <25 Gy
femoral heads constraint
V40<40%, V45<25%, Max , 50 Gy
management for resectable panc
whippe, adj chemo, adj CCRT for positive margin or N+ disease.
Which surgery spares sphincter
LAR
Lab workup for gastric
CBC, CMP, H. pylori, CEA
management of T2N0 esophagus
esophagectomy for select candidates, primary <3cm, well-differentiated
management of cT2+ or N+ gastric cancer
periop chemo, FLOT gastrectomy FLOT, adj CCRT if positive margin or poor responder.
Management for T1N0 rectal
Transanal excision
What nodes to treat in extrahepatic HCC
RPLN, celiac, SM, PH, Gastrohepatic
Anal canal superior edge
palpable upper border of anal sphincter
management of extrahepatic HCC
surgery, LND, adj cape x 6 months, adjuvant CCRT for margin positive, llT2-T4 or any N1, 54 in 30 45 to nodes.
constraints for liver for liver sbrt
Spare 700 cc to < 15 Gy, Mean < 15 Gy
Bladder constraint during rectal rt
V40<40%, V45<15%, Max , 50 Gy
N staging for pancreas
N1: 1-3 LN, N2: 4+ LN
anal margin distance
5 cm from anal verge
labs for pancreatic cancer workpu
CBC/CMP, CA19-9, glucose, amylase, lipase, LDH, CEA
N staging for gastric cancer
N1:1-2LN, N2: 3-6 LN, N3a: 7-15 LN, N3b: 16+ LN
T staging for rectal cancer
T1: invasion of submucosa, T2: muscularis propria, T3: into perirectal tissue, T4a: through visceral peritoneum, T4b: organ invasion
Kidney constraint during panc radiation
V18<30%, if only 1 kidney V18%<10%
lower thoracic esophagus location
30-40 cm
Siewert III
2-5 cm into stomach, treat like gastric.
Anal canal inferior edge
anal verge
cervical esophagus lengths
15-20 cm
Concurrent chemo for anal
CI 5-Fu 1000mg/m2 D1-4 D29-32 + MMC 10 mg/m2 D1 D29 q4w x2. (cisplatin to replace MMC if can’t tolerate)
SB constraint during 5 fraction rectal
Max<25 Gy
High risk colonoscopy screening
q5y starting at age 40
What imaging is needed for pancreas
triphasic CT
SBRT dose for HCC
50 in 5
GE junction location
40-45 cm, GEJ to 5 cm into stomach.
management of T3+ N+ esophagus
preop CCRT
Rectal SB constraint
V35<180 cc, V40<100cc, V45<65cc
workup for T1b+ gastric cancer
diagnostic laparoscopy
Concurrent chemo for rectal
cape: 825 mg/m2 PO BID 5 days/week during RT
Layers of rectum
muscularis mucosa, submucosa, muscularis propria, perirectal fat
T stage for pancreatic cancer
T1a: <=0.5mm, T1b: 5-10mm, T1c: 1-2 cm, T2: 2-4 cm, T3: >4 cm, T4: involves CA, SMA, or CHA
Lab workup for anal
CBC, CMP, HPV, HIV, pregnancy
management of oligometastatic rectal cancer
chemo then short course, restage at 8 weeks and resect primary, SBRT to mets, then additional chemo
Siewert I
1-5 cm above
Stomach max during panc rt
55 Gy max
mid thoracic esophagus location
25-30 cm
Average risk colonscopy screening
age 50 q10 years
management for cTis-T1a gastric cancer
endoscopic resection or gastrectomy, if R0: observe, if R1: adj CCRT, R2: adj CCRT
What is resected in whipple?
panc head and body, distal stomach, duodenum, proximal jejunum, gallbladder, distal CBD.
What are N1 sites for gastric cancer
Lesser curv, greater curv, left/right cardia, suprapyloric, infrapyloric
N stage for anal cancer
N1a: inguinal, perirectal, or internal iliac LN, N1b: external iliac LN, N1c: N1a+N1b
Do you treat common iliac with rectal
only if T4
Management of HCC
resect if possible, ClassA/B no portal HTN
management of cT1b gastric cancer
gastrectomy, R0: observe, R1-R2: adj ccrt (45Gy in 25)
Management of T2N0 rectal
LAR/APR
postop treatemnt T4 or N+ after APR/LAR
FOLFOX then CCRT
Mangement of Intrahepatic cholangio
like HCC
managemenet of unrsectable panc
neoadj folfirinox, restaging, defintive CCRT if needed
What do you need to calculate child’s pugh score
total bili, serum albumin, PT INR, Ascites, Encephalopathy, A5-6, B 7-9, C10-15
T stage anal
T1: <=2cm, T2 2-5, T3: >5, T4: invasion of organs
N2 sites for gastric cancer
Celiac, Left gastric, common hepatic, splenic hilum, splenic artery
management of T1bN0 esgphagus
esophagectomy
T stage for esophagus
T1a: lamina propria or muscularis mucosa, T1b: invades submucosa, T2: invades muscularis propria, T3: invades adventitia, T4a: invades pleura, pericardium, diaphragm, azygos vein, or peritoneum, T4b: invades aorta, vert body, or airway
Do you treat external iliac with rectal
only if T4
upper thoracic esophagus location
20-25 cm
Nonoperative approach for rectal
T1-2N): ccrt, T3 or N+: CCRT then chemo. cCR can observe
Rectal length
12-15 cm
Siewert II
1 to -2 cm around GEJ
What are criteria for no further tx after transanal resection for rectal cancer?
<3cm, margins>3mm, <30% lumen circumference, G1, No LVSI, mobile
Treatment for Tis esophagus
endoscopic resection preferred over esophagectomy
M staging rectal
M1a: 1 DM, M1b: 2+ DM without peritoneal mets, M1c: peritoneal mets
management for borderline resectable pancreas
neoadj folfirinox, restaging, neoadj ccrt if needed
Anal canal length
3-5 cm
chemo for ccrt of esophagus
carboplatin AUC=2, paclitaxel 50 mg/m2 q1w x5
When do you treat nodes for pancreatic
postop
N3 sites for gastric
hepatoduodenal, retropanc, pancreaticoduodenal, peripanc, superior mesenteric, middle colic (N4), para-aortic (N4)
MRI T staging for rectum
T3a<1mm, T3b: 1-5mm, T3c: 5-15 mm, T3d >15 mm
postop treatemnt T1-2N0 after APR/LAR
observe
Liver mean during panc RT
Mean <30 Gy
What LNs to cover when doing RT for gastric cancer
perigastric, celiac, left gastric, splenic artery, common hepatic artery/porta hepatis, suprapyloric/infrapyloric, pancreaticoduodenal
N stage for esophagus
N1: 1-2 LN, N2: 3-6 LN, N3: 7+ LN
Management of cT3-4 or N+ anal
CCRT 45/50.4/54/54, elective, <3cm LN, >3cm LN, primary
postop treatemnt T3N0 after APR/LAR
CCRT then folfox or capeox, consier obs for low grade upper rectum, minimal invasion, no LVSI
Management of T3N0 or higher rectal cancer
TNT
management of T1aN0 esophagus
endoscopic resection preferred over esophagectomy
N staging for rectal cancer
N1a: 1 LN, N1b: 2-3 LN, N1c: No regional LN but tumor deposits in subserosa, mesentery, or non-peritonealized perirectal/mesorectal tissues., N2a: 4-6 LN, N2b: 7+ LN
What if you have high risk features after Transanal excision for rectal cancer
finish with LAR or APR
Heart mean and V30 during panc rt
Mean<30 Gy and V30<20%
Rectal lateral field posterior border
T4: 1 cm behind sacrum T3: 2 cm into sacrum
Rectal lateral field anterior border:
T4: anterior to pubic symphysis, T3: posterior to pubic symphysis